[go: up one dir, main page]

WO2011093820A3 - A pharmaceutical combination comprising tiotropium - Google Patents

A pharmaceutical combination comprising tiotropium Download PDF

Info

Publication number
WO2011093820A3
WO2011093820A3 PCT/TR2011/000022 TR2011000022W WO2011093820A3 WO 2011093820 A3 WO2011093820 A3 WO 2011093820A3 TR 2011000022 W TR2011000022 W TR 2011000022W WO 2011093820 A3 WO2011093820 A3 WO 2011093820A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
pharmaceutical combination
copd
symptomatic
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000022
Other languages
French (fr)
Other versions
WO2011093820A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011093820A2 publication Critical patent/WO2011093820A2/en
Publication of WO2011093820A3 publication Critical patent/WO2011093820A3/en
Priority to US13/531,972 priority Critical patent/US8834931B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising tiotropium bromide, formoterol fumarate and fluticasone propionate, and its use in the symptomatic and/or prophylactic treatment of respiratory diseases especially asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD).
PCT/TR2011/000022 2009-12-25 2011-01-28 A pharmaceutical combination comprising tiotropium Ceased WO2011093820A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00622 2010-01-28
TR2010/00622A TR201000622A2 (en) 2010-01-28 2010-01-28 Pharmaceutical combinations containing tiotropium.

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000023 Continuation-In-Part WO2011105975A1 (en) 2009-12-25 2011-01-28 Dry powder formulations administered by the inhalation route comprising a combination of tiotropium bromide, salmeterol xynafoate and fluticasone propionate.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000021 Continuation-In-Part WO2011093819A2 (en) 2009-12-25 2011-01-28 New combination comprising tiotropium

Publications (2)

Publication Number Publication Date
WO2011093820A2 WO2011093820A2 (en) 2011-08-04
WO2011093820A3 true WO2011093820A3 (en) 2012-02-23

Family

ID=43928910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000022 Ceased WO2011093820A2 (en) 2009-12-25 2011-01-28 A pharmaceutical combination comprising tiotropium

Country Status (2)

Country Link
TR (1) TR201000622A2 (en)
WO (1) WO2011093820A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109219A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium and carmoterol
WO2013109216A2 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising tiotropium
WO2013109209A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising fluticasone
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (en) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Polymorphic form of fluticasone propionate
JP6091862B2 (en) * 2012-11-26 2017-03-08 クリニプロ株式会社 Method for producing inhalable powder
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
GB201409603D0 (en) * 2014-05-30 2014-07-16 Teva Pharmaceuticals Europ B V An inhalable medicament

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US20090188497A1 (en) * 2003-12-03 2009-07-30 Boehringer Ingelheim International Gmbh Medical product containing tiotropium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US20090188497A1 (en) * 2003-12-03 2009-07-30 Boehringer Ingelheim International Gmbh Medical product containing tiotropium

Also Published As

Publication number Publication date
TR201000622A2 (en) 2011-08-22
WO2011093820A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2011093819A3 (en) New pharmaceutical combination comprising tiotropium
WO2011093820A3 (en) A pharmaceutical combination comprising tiotropium
EP2749280A3 (en) Combination of glycopyrronium and formoterol
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
EP2085396A3 (en) Novel crystalline forms of tiotropium bromide
HK1206670A1 (en) Method and apparatus
IL213959A (en) Inhalable corticosteroid, as a nebulized aerosol in the gas phase, for use in the treatment of a patient having severe and uncontrolled asthma
WO2012103216A3 (en) Apparatus and methods for assisting breathing
WO2010094731A3 (en) Pharmaceutical composition for inhalation
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2005074900A3 (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
NO20063879L (en) The combination of anticholinergics and glucocorticoids for long-term treatment of asthma and COPD
WO2009134524A3 (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
TR201000681A2 (en) Dry powder formulations inhaled.
EA201201397A1 (en) INHALER CONTAINING DISTRIBUTED GLISTER PACKING
UA100777C2 (en) Inhalable particles comprising tiotropium
EA201201392A1 (en) PUSH-BUTTON DEVICE
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
WO2011152804A3 (en) Process for dry powder formulations
WO2007099329A3 (en) Nebulizer formulation
IL201632A (en) Use of a composition comprising formoterol and beclometasone dipropionate for manufacture of a medicament administered by inhalation for use in treatment of acute episodes of asthma attacks
EA201201395A1 (en) PUSH-BUTTON DEVICE
EP2120935A4 (en) Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
EA201201389A1 (en) INHALER, CREATING TURBULENCE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11706369

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11706369

Country of ref document: EP

Kind code of ref document: A2